Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Nov 24, 2021 4:20am
647 Views
Post# 34160254

RE:Hemerion Planning Phase 2 Trial at Mt. Sinai NY in 2022

RE:Hemerion Planning Phase 2 Trial at Mt. Sinai NY in 2022Interesting that Eog.

The vaccine farce and their disgraceful treatment of AZ looks unlikely to be the only case where the naked protectionism of the EU leads to poor health outcomes for those under its`control.

Should we take it from your last para that those in Europe with GBM would now have to travel to Toronto if they wished to be treated with Rutherrin?

Chinese disregard of patents is one thing but with regard to healthcare the citizens of the Western World have for decades been victims of politico/corporate stitch-ups that have probably been more damaging to them as end users.

How much further down the road would we be in the humane treatment of disease had the placemen of those with vested interests not inhibited their competitors`progress at every level?




<< Previous
Bullboard Posts
Next >>